Pharmacoeconomic analysis of therapy with reslizumab in severe eosinophilic asthma

The aim of this study was pharmacoeconomic evaluation of treatment with reslizumab compared to omalizumab in severe eosinophilic asthma. Methods. The study was based on indirect comparison between omalizumab and reslizumab in patients with severe asthma using published data. Costs of treatment with omalizumab, reslizumab, combinations of inhaled corticosteroids and long-acting beta-agonists (ICS/LABA), outpatient treatment, treatment of exacerbations and adverse events were also compared. Cost-efficacy analysis and budget impact analysis were used. Results. According to results of cost-efficacy analysis, therapy with reslizumab dominated over therapy with omalizumab in patients with severe asthma in term of rate of exacerbations requiring treatment with systemic steroids. According to results of budget impact analysis, switching of 100 patients from omalizumab to reslizumab could save RUB 51.99 million per a year that corresponds to 36.6% reduction in general direct costs for treatment of severe asthma. Conclusion. The results of this study demonstrated economic advantage of reslizumab over omalizumab in patients with severe eosinophilic asthma.

1. Emel'yanov A.V. Severe asthma. Astma i allergiya. 2013; (3): 16–18 (in Russian).

2. Khamitov R.F., Pal'mova L.Yu., Yakupova Z.N., and Sulbaeva K.R. Sevre asthna: a role of corticosteroids. Vestnik sovremennoy klinicheskoy meditsiny. 2014; 7 (pril. 2): 188–193 (in Russian).

3. Corren J., Weinstein S., Janka L. et al. Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts. Chest. 2016; 150 (4): 799–810. DOI: 10.1016/j.chest.2016.03.018.

4. Chernyak B.A., Vorzheva I.I. Eosinophilic asthma. clinical course and treatment. Doktor.Ru. 2014; 5 (93): 23–29 (in Russian).

5. Castro M., Mathur S., Hargreave F. et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am. J. Respir. Crit. Care Med. 2011; 184 (10): 1125–1132. DOI: 10.1164/rccm.201103-0396OC.

6. Bjermer L., Lemiere C., Maspero J. et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study. Chest. 2016; 150 (4): 789–798. DOI: 10.1016/j.chest.2016.03.032.

7. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Available at: www.ginasthma.org [Accessed: 17.10.2017].

8. Wang F.P., Liu T., Lan Z. et al. Efficacy and safety of anti-interleukin-5 therapy in patients with asthma: a systematic review and meta-analysis. PLoS One. 2016; 11 (11): e0166833. DOI: 10.1371/journal.pone.0166833.

9. Shaporova N.L., Trofimov V.I., Marchenko V.N. Severe asthma. Atmosfera. Pul'monologiya i allergologiya. 2013; 4: 3–6 (in Russian).

10. Castro M., Zangrilli J., Wechsler M.E. et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir. Med. 2015; 3 (5): 355–366. DOI: 10.1016/S2213-2600(15)00042-9.

11. Hanania N.A., Wenzel S., Rosen K. et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am. J. Respir. Crit. Care Med. 2013; 187 (8): 804–811. DOI: 10.1164/rccm.201208-1414OC.

12. Farne H.A., Wilson A., Powell C. et al. Anti-IL5 therapies for asthma. Cochrane Database Syst. Rev. 2017; (9): CD010834. DOI: 10.1002/14651858.CD010834.pub3.

13. Hanania N.A., Alpan O., Hamilos D.L. et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann. Intern. Med. 2011; 154 (9): 573–582. DOI: 10.7326/0003-4819-154-9-201105030-00002.

14. Dávila I., Valero A., Entrenas L.M. et al. Relationship between serum total IgE and disease severity in patients with allergic asthma in Spain. J. Investig. Allergol. Clin. Immunol. 2015; 25 (2): 120–127.

15. Kolbin A.S., Klimko N.N., Andreev B.V. Clinical and economic justification of treatment with Xolair (omalizumab) in bronchial asthma. Kachestvennaya klinicheskaya praktika. 2008; (2): 53–61 (in Russian).

16. Kupryś-Lipińska I., Molińska K., Kuna P. The effect of omalizumab on eosinophilic inflammation of the respiratory tract in patients with allergic asthma. Pneumonol. Alergol. Pol. 2016; 84 (4): 232–243. DOI: 10.5603/PiAP.2016.0029.

17. Humbert M., Beasley R., Ayres J. et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002, step 4 treatment): INNOVATE. Allergy. 2005; 60 (3): 309–316. DOI: 10.1111/j.1398-9995.2004.00772.x.

18. Solèr M., Matz J., Townley R. et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur. Respir. J. 2001; 18 (2): 254–261.

19. Busse W., Corren J., Lanier B.Q. et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J. Allergy Clin. Immunol. 2001; 108 (2): 184–190. DOI: 10.1067/mai.2001.117880.

20. Lai T., Wang S., Xu Z. et al. Long-term efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma: a systematic review and meta-analysis. Sci. Rep. 2015; 5: 8191. DOI: 10.1038/srep08191.

21. Russian Respiratory Society. Clinical Guidelines. Bronchial Asthma. 2016. Available at: http://spulmo.ru/obrazovatelnye-resursy/federalnye-klinicheskie-rekomendatsii (in Russian).

22. Normansell R., Walker S., Milan S. et al. Omalizumab for asthma in adults and children. Cochrane Database Syst. Rev. 2014; (1): CD003559. DOI: 10.1002/14651858.CD003559.pub4.

23. Bousquet J., Cabrera P., Berkman N. et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy. 2005; 60 (3): 302–308. DOI: 10.1111/j.1398-9995.2004.00770.x

24. Walker S., Monteil M., Phelan K. et al. Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst. Rev. 2006; (2): CD003559. DOI: 10.1002/14651858.CD003559.pub3.